OBJECTIVES: Evaluation and comparison of oral antidiabetic drugs (OAD) consumption at state level are an important element at control of 2^ndtype DM patients treatment quality. The objective of the study is to determine the volumes and structure of OAD consumption in Ukraine and to compare it with consumption in the other countries.  METHODS: АТС/DDD-methodology with application of DDD/1000/day (DID). The evaluation is based on consumption volume, provided by “PharmXplorer/Pharmstandard” analytical system of market research.   RESULTS: In year 2008, OAD consumption in Ukraine was 5.78 DID and increased to 11.13 DID in year 2013. In year 2011, OAD consumption was 54.28 DID in France, 44.58 - in Germany (S. Pichetti, C. Sermet, S. van der Erf, 2013), 33.25 - in Estonia, 29.87 - in Latvia (Baltic Statistics on Medicines 2010–2012), showing that OAD consumption in Ukraine was very low. Structure of OAD consumption in Ukraine shows that 98.95% of the total consumption volume is distributed to 2 groups: sulfonylureas (73.84%) and biguanides (25%) and only 1,05% to gliptines, glitazones, glucosidases and glinides. The total share of preparations of sulfonylureas and biguanides group in the total consumption structure in France and Germany was 71.8% and 80.1% respectively of the total consumption OAD. In year 2013, OAD of the II generation - gliclazide (3.01 DID) and glibenclamide (2,09 DID) had the highest consumption level in sulfonylureas group, preparations of III generation - glimepiride (2,09 DID) had lesser consumption rate. Out of 61 OAD trade names (TN), presented in the pharmaceutical market of Ukraine, 8 TNs took 89.78% of the total consumption volume.  CONCLUSIONS: Very low rate of OAD consumption in Ukraine shows the necessity of its increase. Analysis of OAD consumption structure evidences the application of relatively cheap and long-used medical preparations for treatment of 2^nd type DM, which is largely due to financial capacities of payers.